Pro- and antiangiogenic therapies: current status and clinical implications

FASEB J. 2019 Jan;33(1):34-48. doi: 10.1096/fj.201800640RR. Epub 2018 Aug 7.

Abstract

Blood vessels nurture every part of the human body. Consequently, abnormalities in the vasculature are closely associated with a variety of diseases, including cerebral stroke, heart disease, retinopathy, and cancer. Pro- or antiangiogenic therapies can influence these diseases by regulating the growth of new blood vessels from a pre-existing vascular network or dampening excessive blood growth. However, clinical translation of these approaches is slow and challenging. In this review, we discuss recent preclinical approaches to regulate angiogenesis and their potential and risks in a clinical setting.-Rust, R., Gantner, C., Schwab, M. E. Pro- and antiangiogenic therapies: current status and clinical implications.

Keywords: cancer; retinopathy; stroke; vascular repair; vascularization.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inducing Agents / therapeutic use*
  • Angiogenesis Inhibitors / therapeutic use*
  • Humans
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Physiologic / drug effects*

Substances

  • Angiogenesis Inducing Agents
  • Angiogenesis Inhibitors